The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]
Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]
To all the healthcare innovation leaders, urban gerontologists, and care ecosystem designers in the world: if […]
The High Stakes of Innovation: Balancing Takeda’s $1.26B ‘Launch Machine’ and a $2.5B Antitrust Hit as […]
The global pharmaceutical pricing system may be approaching one of its most important structural shifts in […]
Is Shionogi going global as a pharmaceutical company from Japan, or simply buying growth while its […]
Daiichi Sankyo is no longer best understood as a successful Japanese pharma company with a strong […]
Japan wants biotechnology to become a larger part of its economy by 2030. That is the […]
Japan is one of the world’s most demanding healthcare markets. It is also one of the […]